previously untreated RT, irrespective of risk factors and disease stage research hub

A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2

This study compares new drug combinations (pirtobrutinib and epcoritamab) with standard treatment for a type of lymphoma called Richter Transformation. It aims to see if the new treatments stop the cancer from growing for longer. Participants will get either the new drugs or standard chemotherapy.